Skip to main content
. Author manuscript; available in PMC: 2019 Dec 5.
Published in final edited form as: Cell Rep. 2019 Nov 26;29(9):2556–2564.e3. doi: 10.1016/j.celrep.2019.10.092

Figure 4. Type I Interferon Receptor Blockade Rescues Immunopathology Caused by Loss of PD-1 Signaling in LCMV-Infected Mice.

Figure 4.

(A) Survival of LCMV-c13-infected B6 mice treated with anti-IFNAR 1 day prior to infection, anti-PD-L1 (days 0, 2, 4, 6, and 8), or both. Data pooled from 3 experiments with n > 6 mice per group are shown.

(B and C) Frequencies of total CD8 T cells, LCMV-gp33-specific CD8 T cells, and PD-1+ cells in indicated PBMC populations on 8 dpi in LCMV-c13-infected B6 mice with indicated treatment. Representative plots (B) with mean ± SD from 2 experiments (C) are shown.

(D) Plasma LCMV viral RNA load in LCMV-c13-infected B6 mice with indicated treatment from 2 experiments shown with median.

(E) Macroscopic images of spleen and splenocyte counts of LCMV-c-13-infected B6 mice with indicated treatment as in (A) on 22 dpi. Data from two experiments are shown.

See also Figures S3 and S4.